Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials

Alzheimer's and Dementia: Translational Research and Clinical Interventions - Tập 5 - Trang 705-716 - 2019
Carolyn M. Langlois1, Angela Bradbury2, Elisabeth M. Wood2, J. Scott Roberts3, Scott Y.H. Kim4, Marie-Emmanuelle Riviere5, Fonda Liu6, Eric M. Reiman1,7,8,9,10,11, Pierre N. Tariot1, Jason Karlawish12, Jessica B. Langbaum1
1Banner Alzheimer's Institute, Phoenix, AZ, USA
2Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA
3Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI USA
4National Institutes of Health, Bethesda, MD, USA
5Novartis Pharma AG, Basel, Switzerland
6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
7Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ, USA
8Department of Psychiatry, University of Arizona School of Medicine – Phoenix, Phoenix, AZ, USA
9Department of Psychiatry, University of Arizona, Tucson, AZ, USA
10Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
11Arizona Alzheimer's Consortium, Phoenix, AZ, USA
12Departments of Medicine, Medical Ethics and Health Policy, and Neurology, University of Pennsylvania, Philadelphia, PA, USA

Tóm tắt

AbstractIntroductionAs the number of Alzheimer's disease (AD) prevention studies grows, many individuals will need to learn their genetic and/or biomarker risk for the disease to determine trial eligibility. An alternative to traditional models of genetic counseling and disclosure is needed to provide comprehensive standardized counseling and disclosure of apolipoprotein E (APOE) results efficiently, safely, and effectively in the context of AD prevention trials.MethodsA multidisciplinary Genetic Testing, Counseling, and Disclosure Committee was established and charged with operationalizing the Alzheimer's Prevention Initiative (API) Genetic Counseling and Disclosure Process for use in the API Generation Program trials. The objective was to provide consistent information to research participants before and during the APOE counseling and disclosure session using standardized educational and session materials.ResultsThe Genetic Testing, Counseling, and Disclosure Committee created a process consisting of eight components: requirements of APOE testing and reports, psychological readiness assessment, determination of AD risk estimates, guidance for identifying providers of disclosure, predisclosure education, APOE counseling and disclosure session materials, APOE counseling and disclosure session flow, and assessing APOE disclosure impact.DiscussionThe API Genetic Counseling and Disclosure Process provides a framework for large‐scale disclosure of APOE genotype results to study participants and serves as a model for disclosure of biomarker results. The process provides education to participants about the meaning and implication(s) of their APOE results while also incorporating a comprehensive assessment of disclosure impact. Data assessing participant safety and psychological well‐being before and after APOE disclosure are still being collected and will be presented in a future publication.

Tài liệu tham khảo

10.1016/j.jalz.2016.07.150 2018, National Plan to Address Alzheimer's Disease: 2018 Update 10.1016/j.trci.2018.03.009 10.1016/j.trci.2018.02.002 10.1212/WNL.0000000000001451 10.1016/S1474-4422(15)00153-2 10.3233/JAD-150826 10.3233/JAD-2011-0059 Lopez Lopez C., 2017, The Alzheimer's Prevention Initiative Generation Program: evaluating CNP520 efficacy in the prevention of Alzheimer's disease, J Prev Alzheimers Dis, 4, 242 10.1016/j.trci.2019.02.005 10.1097/GIM.0b013e31821d69b8 National Institutes of Health. National Institute on Aging, 2015, Alzheimer's Disease Genetics Fact Sheet 2016, Genetic Testing Protocol for Huntington's Disease 10.1212/WNL.44.8.1533 10.1007/s10897-005-4063-1 10.1056/NEJMoa0809578 10.1111/j.1399-0004.2011.01739.x 10.1038/gim.2017.103 10.1038/ejhg.2010.119 10.1038/gim.2012.37 10.1016/j.jalz.2014.10.014 10.1186/s13195-015-0112-7 10.3233/JAD-170813 10.1300/J018v05n01_09 10.1111/j.2044-8260.1992.tb00997.x 10.1891/1061-3749.17.1.19 10.1176/appi.ajp.2011.10111704 10.1371/journal.pmed.1002254 10.1097/01.GIM.0000132679.92238.58 23andMe, 2019, Alzheimer's Disease (APOE variants): Established Research Report on 2 Reported Markers 10.1038/gim.2012.22 10.1001/jama.1996.03530480027036 10.1177/107327480401100405 10.1097/00006842-197905000-00004 10.1111/1469-7610.00525 10.1002/pon.1323 10.1097/GIM.0b013e3181cef9e1 10.1097/01.GIM.0000151157.13716.6C 10.1093/geront/40.1.43 10.1097/WAD.0b013e318188429e 10.1007/s10897-006-9048-1 10.1037/0278-6133.21.6.564 10.1023/B:JOGC.0000035523.96133.bc 10.1016/S0022-3468(99)90244-0 Alber J., 2017, Recruitment of at‐risk participants for clinical trials: a major paradigm shift for Alzheimer's disease prevention, J Prev Alzheimers Dis, 4, 213 10.1200/JCO.2013.51.3226 10.1097/GIM.0b013e31812e6220 10.1007/s10689-009-9303-3 10.1007/s10689-005-1474-y 10.1016/j.pec.2013.08.009 10.1007/s10897-015-9887-8 Bradbury A.R., 2016, Connect 4 APOE: A Randomized Study of Phone versus Videoconference Delivery of APOE Genotype Disclosure in the Generation Study, 12, P324 10.1159/000455006 10.3233/JAD-179901 10.1016/j.tig.2019.02.005 10.1161/01.cir.0000437741.48606.98
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Tập 5

705-716

Thông tin tác giả